Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.
- DOI
- 10.1038/s41467-026-76662-6
- Published
- 2026 Aug 22
- Container
- Nature communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-026-76662-6,
title = {Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.},
author = {Valero V and Pohlmann PR and Mouabbi J and Huang X and Qiao W and Alonzo H and Murthy RK and Rauch GM and Adesoye T and Checka C and Symmans FW and Grachev D and Alajajyan F and Nwosu-Iheme A and Hassan A and Patel M and Giordano SH and Hunt K and Tripathy D and Meric-Bernstam F},
year = {2026},
journal = {Nature communications},
doi = {10.1038/s41467-026-76662-6},
url = {https://doi.org/10.1038/s41467-026-76662-6}
}RIS
TY - JOUR TI - Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial. AU - Valero V AU - Pohlmann PR AU - Mouabbi J AU - Huang X AU - Qiao W AU - Alonzo H AU - Murthy RK AU - Rauch GM AU - Adesoye T AU - Checka C AU - Symmans FW AU - Grachev D AU - Alajajyan F AU - Nwosu-Iheme A AU - Hassan A AU - Patel M AU - Giordano SH AU - Hunt K AU - Tripathy D AU - Meric-Bernstam F PY - 2026 JO - Nature communications DO - 10.1038/s41467-026-76662-6 UR - https://doi.org/10.1038/s41467-026-76662-6 ER -
APA
V, V., PR, P., J, M., X, H., W, Q., H, A., RK, M., GM, R., T, A., C, C., FW, S., D, G., F, A., A, N., A, H., M, P., SH, G., K, H., D, T., & F, M. (2026). Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.. Nature communications. https://doi.org/10.1038/s41467-026-76662-6
Source records
- pubmed · retrieved 2026-09-26T01:34:20.467Z